Clinical trial · Observational
Antineoplastic Drugs in Elderly Patients
Population Pharmacokinetics, Effectiveness and Safety of Antineoplastic Drugs in Elderly Patients
NCT05467189CI-TRIAL-00059736recruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose is to study the population pharmacokinetics, effectiveness and safety of antineoplastic drugs (Busulfan, Paclitaxel, Afatinib, Ceritinib, Crizotinib, Imatinib, Lapatinib, etc) in elderly patients and recommend optimized dosage regimens.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cancer | Malignant Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Busulfan, Paclitaxel, Afatinib, Ceritinib, Crizotinib (Antineoplastic drugs) | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- treatment
- description
- The use of antineoplastic agents depends on the clinical practice.
- interventionNames
- Drug: Busulfan, Paclitaxel, Afatinib, Ceritinib, Crizotinib (Antineoplastic drugs)
Primary outcomes (3)
- measure
- The peak plasma drug concentration of antineoplastic drugs.
- timeFrame
- at (0-4) hours after administration
- description
- To detect the peak plasma drug concentration of antineoplastic drugs.
- measure
- The random plasma drug concentration of antineoplastic drugs.
- timeFrame
- at (4-10) hours after administration
- description
- To detect the random plasma drug concentration of antineoplastic drugs.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 65 Years
- Maximum age
- 100 Years
Show eligibility criteria text
Inclusion Criteria: Subjects must meet all of the following inclusion criteria to be enrolled in the study: 1. Age ≥65 years old; 2. Diagnosed with cancer; 3. Using antineoplastic drugs for treatment. Exclusion Criteria: Subjects with any of the following criteria will not be enrolled in this study: 1. Patients who are expected to die within 48 hours; 2. Patients with allergy to antineoplastic drugs; 3. Patients receiving other investigational drugs; 4. Other factors that the researcher considers unsuitable for inclusion.
References
Publications (0)
Data not yet available
No reference posted for this study.